Combined application of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in patients with acute leukemia with immune-mediated platelet transfusion failure
By sequentially infusing CD19 CAR-T and BCMA CAR-T cells, antibody-producing cells are targeted and eliminated, solving the problem of ineffective treatment of immune-mediated platelet transfusion failure in existing technologies. This achieves significant improvement in platelet transfusion efficacy and reduction in bleeding risk.
Patent Information
- Application Number
- CN202111305215.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-11-04
AI Technical Summary
Current treatments cannot effectively eliminate anti-HLA and HPA antibodies that cause immune-mediated platelet transfusion to be ineffective, leading to long-term thrombocytopenia in patients, increasing the risk of bleeding and the possibility of transplant failure. Furthermore, existing treatment regimens have problems such as significant side effects and uncertain efficacy.
The sequential infusion of CD19 CAR-T and BCMA CAR-T cells targeted CD19-positive B cells and BCMA-positive plasma cells, respectively, to eliminate antibody-producing cells and prevent the production of platelet-related antibodies.
It significantly improves immune-mediated platelet transfusion ineffectiveness, reduces platelet usage, lowers bleeding risk, shortens hospital stay, improves chemotherapy and transplant success rates, and reduces the likelihood of transplant failure.
Smart Images

Figure CN114558126B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to the combined application of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in the treatment of immune-mediated platelet transfusion failure in patients with acute leukemia. Background Art
[0002] Platelet transfusion refractoriness (PTR) refers to the fact that after two or more ABO-matched platelet transfusions with a storage time of less than 72 hours, the platelet count does not increase significantly or even decreases compared to before transfusion. There are two causes of PTR: non-immune factors and immune factors. Non-immune factors include fever, infection, splenomegaly, disseminated intravascular coagulation, graft-versus-host disease, and certain drugs. Immune factors include ABO blood type incompatibility, anti-human leukocyte antigen (HLA) antibodies and / or anti-human platelet antigen (HPA) antibodies. The production of anti-HLA antibodies is mainly related to multiple pregnancies and repeated blood transfusions.
[0003] More than 50% of patients who receive long-term and repeated platelet transfusions will develop platelet alloantibodies. These alloantibodies mediate platelet destruction, with a PTR incidence rate as high as 30-70%. The higher the antibody titer, the greater the probability of PTR.
[0004] In addition, the production of anti-HLA antibodies is also closely related to the occurrence of PTR. It has been reported that the PTR incidence in AML patients with positive HLA-I antibodies is 83.3%. The number of platelet transfusions is proportional to the incidence of PTR. Acute myeloid leukemia (AML) causes bone marrow suppression and thrombocytopenia due to chemotherapy, immune factors and other reasons, and requires repeated platelet transfusions, which makes PTR more likely to occur.
[0005] Patients who are ineffective with platelet transfusions have long-term thrombocytopenia that cannot be corrected, and are prone to bleeding in important organs and the brain. In severe cases, there is a risk of death, and some AML patients lose the opportunity for hematopoietic stem cell transplantation (HSCT). Studies have also confirmed that HLA antibody-positive patients have delayed neutrophil and platelet engraftment after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and even have engraftment failure, a high incidence of graft-versus-host disease after transplantation, a high mortality rate in the early stage of transplantation, and a short long-term overall survival time.
[0006] Currently, the best way to treat immune-mediated PTR is to transfuse cross-matched platelets or HLA and HPA matched platelets. Although they are considered the gold standard for treatment, neither of these two methods is supported by high-quality evidence, and about 40-60% of patients still have not effectively improved PTR. Due to the high polymorphism of the HLA system, a very large donor pool is required, but my country does not have a complete HLA and HPA gene pool. For patients with multiple antibody specificities or rare HLA phenotypes, the chance of obtaining a compatible donor is even lower, and due to the severe shortage of blood products, it is more difficult to implement platelet matching transfusions.
[0007] Traditional treatments for PTR include plasma exchange, splenectomy, high-dose intravenous immunoglobulin (IVIG), rituximab, immunosuppressants, and bortezomib, but all have their limitations. Plasma exchange can only remove pre-existing (already produced) platelet antibodies, but cannot prevent the subsequent production of platelet antibodies. In addition, plasma exchange can be maintained for a short time, and antibody titers may rebound when stem cells are transfused.
[0008] The spleen is the site where platelets are destroyed and is also the area where terminally differentiated plasma cells that produce antibodies remain. Splenectomy can reduce platelet destruction and the retention of plasmablasts, but it is an invasive surgery with surgical risks in patients with thrombocytopenia. It cannot remove plasma cells in the bone marrow and cannot change the number and type of anti-HLA antibodies.
[0009] IVIG can improve the effect of platelet transfusion in patients with autoimmune thrombocytopenia, but its effect on PTR treatment is limited, so it is generally only used for the rescue of life-threatening bleeding. Rituximab can quickly eliminate B cells expressing CD20 in the circulation and inhibit the generation of short-lived plasmablasts, but the terminally differentiated plasma cells that have been generated do not express CD20, and the antibodies that can be continuously secreted make it difficult to correct PTR. Moreover, the clearance effect of rituximab on CD20-expressing B cells is temporary, and B cells gradually return to normal after 2-3 months.
[0010] Immunosuppressants such as cyclophosphamide can inhibit allogeneic immunity to a certain extent, and have side effects such as cardiac and liver toxicity and bone marrow suppression. It takes at least 2-3 weeks for the antibody titer to decrease. It is not suitable for patients who need to immediately improve the platelet count and patients who need transplantation. Some researchers have observed that after bortezomib combined with dexamethasone was used to treat multiple myeloma, serum IgG decreased, HLA-I class antibodies decreased significantly, and the PTR status was improved, but it was only a case report, and the efficacy is still controversial. Bortezomib can cause peripheral neuropathy and intestinal obstruction after use, and has significant side effects. In summary, the existing PTR treatment regimen has problems such as short maintenance time, uncertain efficacy, and large side effects. Therefore, new methods are urgently needed to treat PTR so that patients can benefit lastingly.
[0011] The key to PTR treatment is to eliminate antibodies and antibody-secreting cells. Antibodies are relatively short-lived proteins with a serum half-life of 1 week to 1 month, but antigen-specific antibody responses can last a lifetime, so plasma cells that produce antigen-specific antibodies continue to exist. Plasma cells are the terminal stage of B lymphocyte differentiation and have almost lost B cell markers (such as CD20 and surface immunoglobulin [Ig]). A plasma cell secretes more than 3,000 antibodies per second, which is 3,700 times more potent than effector B cells. There are two types of plasma cells: short-lived plasmablasts that mainly exist in the spleen or lymph nodes, and long-lived plasma cells (Long-Lived Plasma Cells, LLPCs) that mainly exist in the bone marrow. The short-lived plasma cells that have been widely studied usually die within 3-5 days; LLPCs produce persistent antigen-specific antibodies, migrate to the bone marrow niche, and can persist throughout the animal's life. LLPCs cannot be eliminated by conventional immunosuppression and B cell-targeted therapies, such as cyclophosphamide or anti-CD20 therapy, because they do not express CD20 and are mostly in the G0 / G1 phase without cell division and do not respond to antigens or antibody-antigen complexes.
[0012] Bone marrow LLPCs are considered to be the main source of IgG, and most clinically relevant HLA antibodies have been confirmed to be IgG. Therefore, the clearance of anti-HLA and anti-HPA related antibodies requires the clearance of B cells and terminally differentiated plasma cells (especially long-lived plasma cells).
[0013] In recent years, the application of chimeric antigen receptor T cells (CAR-T) has become more and more widespread, and has achieved excellent therapeutic effects in clinical trials of blood system tumors such as B-lineage acute lymphoblastic leukemia / lymphoma and multiple myeloma. In addition to blood system malignancies and solid tumors, progress has also been made in immune thrombocytopenia and autoimmune diseases. In a systemic lupus erythematosus mouse model, CD19 CAR-T cell therapy can continuously eliminate B cells, reduce autoantibody secretion, reverse damage to target organs such as kidneys and skin, shrink the spleen, and significantly prolong the survival of mice.
[0014] In the dynamic monitoring of humoral immunity after CD19+CAR-T cell treatment of B cell malignancies, it was found that no B cells were detected during the follow-up period, but the IgG of specific pathogens such as measles, mumps, influenza, and pneumococcus remained stable in the peripheral blood, indicating that antibody-producing plasma cells continued to exist in the case of B cell exhaustion. In addition, some researchers have detected that after CD19 CAR-T cell treatment, anti-HLA antibodies B49 and A26 were continuously and stably expressed in the peripheral blood during the 22-month follow-up, when no circulating B cells were detected, and the mean fluorescence intensity (MFI) value of HLA antibody B49 was stably expressed at around 10000U. The above results show that targeting CD19 can eliminate some antibody-producing cells, but cannot target a considerable number of plasma cells that do not express CD19. Current evidence shows that bone marrow LLPCs are mainly CD19- and do not rely on or rarely rely on the supplementation of peripheral plasma blasts.
[0015] CD19 is a B lymphocyte-specific surface protein, a component of the B cell co-receptor complex, and belongs to the immunoglobulin superfamily. It is expressed throughout the differentiation process from pre-B cells to mature B cells, but existing evidence shows that most LLPCs are CD19 negative. B cell maturation antigen (BCMA) is a member of the TNF receptor superfamily and a cell surface protein expressed in terminally differentiated B cells and plasma cells. It is highly expressed on the surface of malignant plasma cells, but rarely expressed in hematopoietic stem cells and non-hematopoietic tissues. Some researchers have found that after knocking out the Tnfrsfl7 gene (encoding BCMA) in mice, antibody-secreting cells in the bone marrow were significantly lost 6-8 weeks after immunization, while germinal center reactions and early antigen-specific serum IgM and IgG titers were normal, indicating that BCMA loss mainly affects LLPC subsets.
[0016] In view of the high selectivity of BCMA-targeted therapy for myeloma cells and PC populations in multiple myeloma patients, combined with the successful experience of BCMA-targeted CAR-T cells in MM treatment, CAR-T targeting CD19 and BCMA is likely to completely eliminate B cells and plasma cells in the body. Such CAR-T combination therapy will prevent the survival of new B cells and prevent the production of new plasma cells. At the same time, existing plasma cells can be completely eliminated, thereby improving or correcting PTR. Summary of the invention
[0017] In order to overcome the above-mentioned defects of the prior art, the purpose of the present invention is to provide a combined application of sequential infusion of CD19CAR-T and BCMA CAR-T cells in patients with acute leukemia with ineffective immune-mediated platelet transfusion. The combined application overcomes the defect of ineffective immune-mediated platelet transfusion in patients with acute leukemia without obvious toxic side effects.
[0018] In order to achieve the purpose of the present invention, the technical solution adopted is:
[0019] The combined use of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in patients with acute leukemia with immune-mediated platelet transfusion failure, wherein the combined use is:
[0020] CD19 CAR-T cells: Infusion dose: (1.0-2.0)×10 7 / kg, 40% and 60% of the total dose were transfused on 01d and 02d; BCMACAR-T cells: transfusion dose: (1.0-2.0)×10 7 / kg, 40% and 60% of the total dose were reinfused on 03d and 04d.
[0021] In a preferred embodiment of the present invention, the acute leukemia patient is an acute myeloid leukemia patient or an acute lymphocytic leukemia patient.
[0022] In a preferred embodiment of the present invention, the acute leukemia patient is a patient with acute leukemia in remission and ineffective platelet transfusion.
[0023] In a preferred embodiment of the present invention, the patient's platelet transfusion ineffectiveness is caused by immune factors.
[0024] The beneficial effects of the present invention are:
[0025] It is used for patients with acute leukemia in remission and immune-mediated platelet transfusion failure. Its innovation lies in the combined use of CD19 and BCMA as targets to continuously eliminate CD19-positive B cells and BCMA-positive plasma cells in the body, block the production pathway of platelet-associated antibodies (PAA, mainly HLA and HPA antibodies), and improve antibody-mediated platelet transfusion failure. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of the changes in platelet count after blood transfusion during the bone marrow suppression period before and after sequential CAR-T cell infusion therapy in Case 1.
[0027] Figure 2 Schematic diagram of the changes in HLA antibody MFI before and after sequential infusion of CAR-T cells in Case 1.
[0028] Figure 3 Schematic diagram of the change in PAA score before and after sequential infusion of CAR-T cells in case 1.
[0029] Figure 4 This is a schematic diagram of the changes in platelet count after blood transfusion during the bone marrow suppression period before and after sequential CAR-T cell infusion therapy in Case 2.
[0030] Figure 5 Schematic diagram of the changes in HLA antibody MFI values before and after sequential infusion of CAR-T cells in Case 2.
[0031] Figure 6 Schematic diagram of the change in PAA score before and after sequential infusion of CAR-T cells in case 2. DETAILED DESCRIPTION
[0032] The present invention will be further described below with reference to specific cases.
[0033] Case 1:
[0034] A 38-year-old female patient, diagnosed with acute myeloid leukemia (M2), had a history of pregnancy and was admitted to the hospital for fever in September 2019. The blood routine test showed: WBC 5.97×10 9 / L,NE 3.62×10 9 / L, HB 69g / L, PLT 13×10 9 / L, transferred to a local hospital, received comprehensive treatment such as blood transfusion, and completed bone marrow biopsy on 09-16. Morphology: bone marrow hyperplasia is active and high, with 20.5% of blasts, AML-M2 is not excluded; white rabbit: analysis of 26.6% of the blast population showed myeloid antigen expression, and 57.5% of the granulocyte differentiation antigens were abnormally expressed, which was consistent with the AML-M2 phenotype, so he was treated in our hospital. Peripheral blood blasts were 22%. Chromosomes: 46XX, t(8;21)(q22;q22)[7] / 45, idem, -X[3]. Bone marrow multiplex PCR: AML1-ETO fusion gene transcripts were detected. The relative expression of WT1 gene transcripts was 2.54%, and the relative expression of EVI1 gene transcripts was 0.04%. The patient was diagnosed with AML and received chemotherapy with a full course of decitabine + homoharringtonine + aclarubicin + cytarabine + granulocyte colony-stimulating factor (DAC+HAAG) from September 25, 2019. The patient had persistent thrombocytopenia before and after chemotherapy (platelet count <10×10 9 / L for 34 days), and no significant increase after platelet transfusion, indicating that random donor platelet transfusion was ineffective (see Figure 1 ).
[0035] Physical examination: clear consciousness, good spirits, no signs of anemia, a skin ecchymosis of about 7cm×6cm can be seen on the left upper arm, no icteric sclera, no superficial lymph node enlargement. No tenderness in the sternum, clear breath sounds in both lungs, no dry or wet hiccups, regular heart rhythm, no pathological murmurs. The abdomen is flat and soft, without tenderness or rebound tenderness, and the liver and spleen are not palpable under the ribs. No edema in both lower limbs.
[0036] Auxiliary examination: positive antinuclear antibody spectrum, strongly positive PAA screening, HLA antibody screening for HLA-I class, HLA-II class (using immunomagnetic bead flow cytometry liquid phase chip technology, Luminex method), 17 anti-HLA-I class antibody sites with MFI values > 10000 (among which A32, A68, A69, A33, and A23 have MFI values of 22764, 22581, 22324, 22304, and 21956, respectively).
[0037] Treatment: The patient received 9 plasma exchange sessions and 6 doses of rituximab (375 mg / m 2 / time) and 2 courses of intravenous human immunoglobulin (0.4g / kg / day, 5 days as a course), but these therapies did not cause an increase in platelet count after transfusion, the HLA antibody MFI value increased again within a short period after a decrease, and the PAA test continued to be strongly positive.
[0038] Therefore, the patient received sequential infusion of CD19 and BCMA CAR-T cells (infusion method: CD19 CAR-T cells: 0.8×10 7 / kg,02d 1.2×10 7 / kg; BCMA CAR-T cells: 0.8×10 on day 03 7 / kg,04d 1.2×10 7 / kg), no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and non-hematology-related toxicity occurred, and grade 4 hematological toxicity was observed, which recovered within 3 weeks after CAR-T, which was considered to be related to the use of the conditioning regimen.
[0039] Combination Figure 1 , Figure 1 The circular and square lines are respectively when the disease was first diagnosed and after traditional treatment, the bone marrow suppression period after chemotherapy, and the platelet count remained in a critical value state (<10×10 9 / L) After repeated platelet transfusion, there was no significant increase, which was manifested as PTR; the triangle mark line is after sequential CAR-T cell infusion therapy, the bone marrow suppression period after chemotherapy, after the patient's platelet count decreased, and after platelet transfusion, there was a significant increase in platelet count, and PTR was significantly improved compared with before treatment. The solid arrow indicates the transfusion of 10U platelets, and the dotted arrow indicates the transfusion of 5U platelets.
[0040] Efficacy: 8 weeks after treatment, the antinuclear antibody spectrum was negative, and the MFI values of multiple HLA sites dropped to below 5000 or turned negative. Allogeneic hematopoietic stem cell transplantation was successfully performed. Platelet transfusion during the bone marrow suppression period after pretreatment increased significantly, and PTR was significantly improved (see Figure 1 ). PAA and HLA antibodies were rechecked 4 months after CAR-T, and both turned negative ( Figure 2 , Figure 3 ).
[0041] Figure 2 Among them, the patient's multiple HLA loci were strongly positive when AML was first treated. After treatment with various methods (plasma exchange, rituximab, intravenous human immunoglobulin), the HLA value was still at a high level. After sequential infusion of CAR-T cells, HLA gradually decreased to negative, and allogeneic hematopoietic stem cell transplantation was successfully performed. Subsequent follow-up was negative.
[0042] Figure 3Among them, the patient's PAA screening was strongly positive when AML was first treated. After treatment with various methods (plasma exchange, rituximab, intravenous human immunoglobulin), the PAA score remained at a high level. After sequential infusion of CAR-T cells, the PAA score gradually dropped to negative, and allogeneic hematopoietic stem cell transplantation was successfully performed. Subsequent follow-up was negative.
[0043] Case 2:
[0044] A 30-year-old female patient, diagnosed with acute lymphoblastic leukemia (Ph positive), with a history of pregnancy, was admitted to the hospital in December 2019 for "repeated cough and sputum for 2 months, chest tightness and chest pain for 5 days". The blood routine test showed: WBC 4.82×10 9 / L, HB 104g / L, PLT 59×10 9 / L; chromosome: 46, XX
[10] ; multiplex PCR: BCR-ABL (+), WT 171.36%, diagnosed as Ph-positive acute B lymphoblastic leukemia. Physical examination: T: 36.7℃, P: 92 times / min, R: 18 times / min, BP: 121 / 71mmHg. Conscious, mentally sound, mild anemia, no petechiae or ecchymosis on the skin and mucous membranes, several peanut-sized lymph nodes in the right submandibular and right neck, no tenderness on the sternum, clear breath sounds in both lungs, no dry or wet hiccups, spleen about 3cm below the ribs. The first course of chemotherapy was nilotinib + vindesine + dexamethasone, during which thrombocytopenia occurred, which did not increase significantly after multiple platelet transfusions, and platelet transfusions were ineffective.
[0045] Auxiliary examination: PAA antibody screening was strongly positive, HLA antibody screening was HLA-I class, and the MFI values of 5 HLA antibody sites were >10000 (the MFI values of B58, B41, B59, B39, and B27 were 12542, 12207, 11779, 11496, and 11034, respectively). Therefore, it was diagnosed as HLA antibody-mediated PTR.
[0046] Treatment: For platelet transfusion failure and antibody positivity, 6 plasma exchanges and 3 doses of rituximab (375 mg / m 2 After 1 course of intravenous human immunoglobulin (0.4 g / kg / day, 5 days as a course), anti-HLA antibodies did not decrease significantly, and platelet transfusion was still ineffective. The patient received CD19 and BCMA CAR-T cell sequential infusion therapy (infusion method: CD19 CAR-T cells: 0.8×10 7 / kg,02d 1.2×10 7 / kg; BCMA CAR-T cells: 0.8×10 on day 03 7 / kg,04d 1.2×10 7 / kg), no CRS, ICANS and non-hematology-related toxicity occurred, and grade tertiary hematological toxicity was observed, which recovered within 3 weeks after CAR-T, which was considered to be related to the use of the conditioning regimen.
[0047] Efficacy: After CAR-T cell infusion, the patient's HLA antibody MFI value gradually decreased. At 8 weeks after CAR-T, the MFI values of multiple sites dropped to below 5000 or turned negative. Allogeneic hematopoietic stem cell transplantation was successfully performed. After the random donor platelet transfusion during the bone marrow suppression period after pretreatment, the platelet count increased significantly, and PTR was effectively improved ( Figure 4 ). PAA and HLA antibodies were re-examined 16 weeks after CAR-T, and both turned negative ( Figure 5 , Figure 6 ).
[0048] In summary, the present invention improves the ineffectiveness of platelet transfusion in PTR patients by sequentially infusing CD19 CAR-T and BCMA CAR-T cells, reduces the use of platelets, reduces the risk of bleeding and death; shortens the average length of hospital stay; eliminates B cells and plasma cells, reduces the production of HLA-related antibodies, reduces the possibility of death due to major bleeding complications caused by bleeding in subsequent chemotherapy and transplantation caused by ineffective platelet transfusion, and prevents the failure of allogeneic stem cell transplantation.
Claims
1. Use of a sequential infusion drug in the preparation of a drug for improving immune-mediated platelet transfusion failure in patients with acute leukemia, It is characterized in that The sequential infusion drugs are: CD19 CAR-T cells: infusion dose: (1.0-2.0)×10 7 / kg, 40% and 60% of the total dose were infused on 01d and 02d; and BCMA CAR-T cells: the infusion dose was: (1.0-2.0)×10 7 / kg, and 40% and 60% of the total reinfusion dose were reinfused on 03d and 04d. The patient was an acute leukemia patient in remission and ineffective immune-mediated platelet transfusion.
